Royalty Pharma PLC (RPRX) News
Filter RPRX News Items
RPRX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
RPRX News Highlights
- RPRX's 30 day story count now stands at 3.
- Over the past 14 days, the trend for RPRX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about RPRX are DRUG, GENE and SPR.
Latest RPRX News From Around the Web
Below are the latest news stories about ROYALTY PHARMA PLC that investors may wish to consider to help them evaluate RPRX as an investment opportunity.
Royalty Pharma Raises Full Year 2023 GuidanceRoyalty Pharma now expects 2023 Adjusted Cash Receipts(1) (non-GAAP) to be between $2,850 million and $2,950 million, excluding contributions from future transactions NEW YORK, March 15, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has received a $475 million accelerated milestone payment from Pfizer, following the U.S. Food and Drug Administration (FDA) approval of Zavzpret (zavegepant), a calcitonin gene-related peptide (CGRP) receptor antagonist nasal spr |
Optimism around Royalty Pharma (NASDAQ:RPRX) delivering new earnings growth may be shrinking as stock declines 3.5% this past weekIt's easy to match the overall market return by buying an index fund. While individual stocks can be big winners... |
Royalty Pharma Appoints Ashwin Pai as Executive Vice President, InvestmentsNEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Ashwin Pai, M.D. as Executive Vice President, Investments. Ashwin will join Royalty Pharma in April 2023, and will report to Chris Hite, Executive Vice President and Vice Chairman. Ashwin joins Royalty Pharma from Morgan Stanley where he was a Managing Director and Head of West Coast Biotechnology Investment Banking. In his nearly two decade career, Ashwin has been involved in some o |
Royalty Pharma Reports Q4 and Full Year 2022 ResultsNet cash provided by operating activities (GAAP) of $570 million and Adjusted Cash Receipts(1) (non-GAAP) of $1,064 million in Q4 2022Announced transactions of up to $3.5 billion in 2022, including $2.0 billion in upfront paymentsFull year 2023 guidance: Adjusted Cash Receipts(1) (non-GAAP) of $2,375 to $2,475 million; excludes potential zavegepant approval milestone of $475 million NEW YORK, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for |
Royalty Pharma to Present at Upcoming Investor ConferencesNEW YORK, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the months of February and March: SVB Securities Global Biopharma Conference on Thursday, February 16 at 10:40 a.m. ETCowen 43rd Annual Health Care Conference on Tuesday, March 7 at 11:10 a.m. ET The webcasts will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/news-and-events/even |
Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be Increased To $0.20Royalty Pharma plc ( NASDAQ:RPRX ) will increase its dividend from last year's comparable payment on the 15th of March... |
Royalty Pharma To Announce Fourth Quarter And Full Year 2022 Financial Results On February 15, 2023NEW YORK, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2022 financial results on Wednesday, February 15, 2023 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Conference Call Information Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/news-and-events/events to o |
Royalty Pharma's (NASDAQ:RPRX) Shareholders Will Receive A Bigger Dividend Than Last YearThe board of Royalty Pharma plc ( NASDAQ:RPRX ) has announced that it will be increasing its dividend by 5.3% on the... |
Royalty Pharma Highlights Accomplishments and Provides Business Update at 41st Annual J.P. Morgan Healthcare Conference2022 Net cash provided by operating activities (GAAP) expected to be approximately $2,140 million to $2,150 million; 2022 Adjusted Cash Receipts(1) (non-GAAP) expected to be approximately $2,785 million to $2,790 million, towards the upper end of guidance range Announced transactions of $10 billion since 2020 expected to add ~$1 billion to Adjusted Cash Receipts(1) (non-GAAP) in 2025 NEW YORK, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today provided an update on its bus |
Royalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis’ Genetic Medicines and Commercial ReadinessRoyalty Pharma to acquire an interest in SPINRAZA® and pelacarsen royalties – Ionis retains majority of royalties and all milestones from Novartis for pelacarsenRoyalty Pharma to pay Ionis $500 million upfront and up to $625 million in milestonesAgreement enables Ionis to achieve commercial readiness for multiple late-stage programs and advance its innovative pipeline of genetic medicines NEW YORK and CARLSBAD, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Ionis |